Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jeanne F. Noe"'
Autor:
Aaron D. Falchook, MD, Gregg Tracton, BS, Lori Stravers, MPH, CHES, Mary E. Fleming, ANP, Anna C. Snavely, PhD, Jeanne F. Noe, PharmD, David N. Hayes, MD, MPH, Juneko E. Grilley-Olson, MD, Jared M. Weiss, MD, Bryce B. Reeve, PhD, Ethan M. Basch, MD, Bhishamjit S. Chera, MD
Publikováno v:
Advances in Radiation Oncology, Vol 1, Iss 2, Pp 115-121 (2016)
Purpose: Accurate assessment of toxicity allows for timely delivery of supportive measures during radiation therapy for head and neck cancer. The current paradigm requires weekly evaluation of patients by a provider. The purpose of this study is to e
Externí odkaz:
https://doaj.org/article/f6a9d2db252b408daed25d3320aeb23d
Autor:
Jeanne F. Noe, Margaret A. Bush
Publikováno v:
The Journal for Nurse Practitioners. 17:177-181
Endocrine therapy is the primary treatment for the most common types of breast cancer. Endocrine agents work by inhibiting the tumor-stimulating effects of estrogen in hormone-sensitive tumors. A new class of targeted drugs synergize with endocrine a
Autor:
Oludamilola Olajide, Allison M. Deal, Nilanjan Ghosh, Jeanne F. Noe, Stephen M. Ansell, Thomas C. Shea, Nishitha Reddy, Steven I. Park, Lihua E. Budde
Publikováno v:
Blood Adv
Approximately 90% of limited-stage Hodgkin lymphoma (HL) patients are projected to be cured with standard therapy, but many do not live their expected life span because of late treatment–related complications. New treatment paradigms are needed to
Autor:
Peggy A. Bush, Jeanne F. Noe
Publikováno v:
The Journal for Nurse Practitioners. 16:195-200
Treatment of cancer has shifted dramatically over the past 2 decades. Targeted agents are used to block pathways known to drive tumor growth. Immunotherapy agents work by reversing cancer’s ability to evade immune checkpoints, resulting in effectiv
Autor:
L. Stravers, Ethan Basch, Juneko E. Grilley-Olson, Anna C. Snavely, Mary Fleming, Gregg Tracton, David N. Hayes, Jared Weiss, Bryce B. Reeve, Aaron D. Falchook, Jeanne F. Noe, Bhishamjit S. Chera
Publikováno v:
Advances in Radiation Oncology, Vol 1, Iss 2, Pp 115-121 (2016)
Advances in Radiation Oncology
Advances in Radiation Oncology
Purpose Accurate assessment of toxicity allows for timely delivery of supportive measures during radiation therapy for head and neck cancer. The current paradigm requires weekly evaluation of patients by a provider. The purpose of this study is to ev
Autor:
Jeanne F. Noe, Kristy L. Richards, Steven I. Park, O. Olajide, Nilanjan Ghosh, Lihua E. Budde, S. M. Ansell, Thomas C. Shea, N.M. Reddy, Allison M. Deal
Publikováno v:
Hematological Oncology. 35:81-82
Autor:
Hyman B. Muss, Jeanne F. Noe
Publikováno v:
Cancer and Aging Handbook
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::950911447aba01e3087bea60ce66178c
https://doi.org/10.1002/9781118312513.ch5
https://doi.org/10.1002/9781118312513.ch5
Autor:
Kristy L. Richards, Oludamilola Olajide, Nilanjan Ghosh, Jeanne F. Noe, Allison M. Deal, Matthew C. Foster, Elizabeth Budde, Thomas C. Shea, Nishitha Reddy, Stephen M. Ansell, Steven I. Park
Publikováno v:
Blood. 124:4431-4431
Background: Treatment of Hodgkin lymphoma (HL) requires a careful balance between providing enough therapy to cure the disease and avoiding unnecessary treatment that could result in excessive long-term treatment-related complications. The preferred
Autor:
Carey K. Anders, Hyman B. Muss, Elizabeth Claire Dees, William J. Irvin, Lisa A. Carey, Olga Karginova, Allison M. Deal, Barbara Adamo, Aleix Prat, Jeanne F. Noe
Publikováno v:
Journal of Clinical Oncology. 30:TPS656-TPS656
TPS656 Background: HER2+ breast cancer (BC) is an aggressive subset of BC with high rates of brain metastases (BM) and poor survival. A recent study illustrates activation of the PI3K/mTOR pathway in approximately two-thirds of BCBM across all subtyp